Effect of Treatment With Butyric Acid in Anorexia Nervosa
Key facts
- Who runs it
- Azienda Ospedaliero-Universitaria Careggi
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 50 people, planned
- Started
- 12 Nov 2025
- Expected to end
- 12 Nov 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Dietary Supplement: Butyric Acid
- Record updated
- 17 December 2025
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
Show the full registry criteria (19)Hide the full registry criteria
Who can take part
- Female sex
- Age 18-65 years
- Current diagnosis of Anorexia Nervosa (DSM-5)
- Able and willing to provide informed consent
- Ability to comply with study procedures and assessments
Who cannot take part
- Corticosteroid therapy within the past 6 months
- Severe psychiatric conditions requiring inpatient hospitalization (e.g., psychosis, severe major depressive episode with suicidal intent)
- Severe medical conditions requiring inpatient care (cardiovascular, renal, hematopoietic, gastrointestinal, endocrine disorders)
- Intellectual disability, illiteracy, or conditions impairing consent or questionnaire completion
- Radiological evidence of toxic megacolon or intestinal perforation
- Active or past malignancy requiring chemotherapy
- HIV infection
- Neutropenia (<0.5 × 10\^9/L)
- Leukocytosis (>30 × 10\^9/L)
- Current participation in another experimental protocol
- Active use of probiotics
- Fever > 38°C
- Presence of colostomy
- Severe comorbidity limiting 30-day survival
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This clinical trial aims to evaluate the therapeutic potential of oral butyric acid supplementation in individuals with anorexia nervosa (AN). T The study will assess whether butyric acid, administered alongside standard multidisciplinary care, improves weight restoration and contributes to overall clinical recovery.
Read full original descriptionShow less
The primary objectives are to determine:
- Whether butyric acid enhances weight restoration during the first 3 months of treatment.
Participants will be randomly assigned to receive either butyric acid or a placebo for 3 months, in addition to treatment-as-usual, which includes nutritional rehabilitation and cognitive-behavioral therapy.
Throughout the study, researchers will monitor:
* Changes in body weight and Body Mass Index (BMI) * General and eating-disorder-related psychopathology * Blood-based biomarkers related to inflammation, metabolism, and neuroendocrine function * Gut microbiota composition and metabolites, including short-chain fatty acids
A total of 50 participants with AN are expected to be enrolled.
The 2 groups in the trial
- Active Comparator: Butyric AcidExisting treatment, for comparison
Participants with anorexia nervosa receiving butyric acid supplementation plus Treatment As Usual.
Treatment: Dietary Supplement: Butyric Acid
- Placebo Comparator: PlaceboPlacebo, for comparison
Participants with anorexia nervosa receiving placebo capsules plus Treatment As Usual.
Treatment: Dietary Supplement: Butyric Acid
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effetto Del Trattamento Con Acido Butirrico Sull'Anoressia Nervosa
- Record updated
- 17 December 2025